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The posttranslational reversible acetylation on the ε-
amino-group of lysines is an important switch in gene 
regulation and protein activity and has gained increasing 
interest in molecular biology and drug discovery in the last 
decade. One of the enzyme families that catalyze the 
cleavage of an acetyl group are the NAD+-dependent 
protein deacetylases, the sirtuins. The human sirtuins have 
seven members, Sirt1-7. Even though the biology of the 
sirtuins is far from being fully understood, there is already 
ample evidence that they may serve as future therapeutic 
targets. Their activity has especially been connected to 
processes in aging and hence, the field of potential 
applications for sirtuin modulators is very wide, ranging 
from neurodegenerative diseases to cancer to diabetes [1]. 
Some in vivo studies with sirtuin modulators, like the 
potential activator resveratrol  or the inhibitor AGK2, 
show already great promise [2,3]. 
Several classes of sirtuin inhibitors with diverse chemical 
scaffolds have been published so far, but there is lack of 
highly specific inhibitors for only one of the seven sirtuin 
isoforms. Often only Sirt1 and 2 have been tested [4]. This 
lack of specific inhibitors may be partly because of the 
lack of high-resolution sirtuin-inhibitor x-ray structures but 
also due to the fact that the binding of the substrate is 
accompanied by a structural reshuffling of the substrate 
pocket [5].  Sirtuin isoforms are located in different 
cellular compartments and permeability of the 
compartment’s membrane for the inhibitor may be a 
limiting factor, especially for the mitochondrial sirtuins 
Sirt3-5. For a selective inhibition of nuclear and 
cytoplasmatic sirtuins (Sirt1-2, 6-7) this might actually be 
favorable. Schlicker et al. now used virtual screening and 
docking methods [6], an approach that has already been 
successfully applied for the discovery of other sirtuin 
inhibitors [7], to identify new isoform-specific inhibitors. 
Two of the newly identified lead structures for the Sirt2-
specific inhibitors contain a steroid scaffold and one of 
them is an ester of estradiol. The steroid scaffold brings 
along potential disadvantages due to possible interactions 
with steroid receptors. As there is ample knowledge in the 
literaure on modifications of the steroid scaffold, this could 
be used to eliminate such undesired side effects in further 
steroid-type sirtuin inhibitors. Besides the inhibition in 
vitro, the authors also showed the isoform-specific 
inhibition of Sirt2 in cell lysates as a more physiological 
environment but not in living cells.  
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This was due to the high cytotoxicity of the tested 
compounds but it was not clear if the cytotoxicity was a 
result of the Sirt2-inhibition. Nevertheless, the new 
findings should serve as a very good starting point for the 
identification of new potent and isoform-specific 
inhibitors. These are certainly needed for functional 
studies to shed light on the underlying cellular mechanisms 
for the different sirtuin isotypes and on their potential role 
as therapeutical targets or antitargets. The identification of 
the steroid scaffold as a sirtuin interacting structure is also 
very interesting for a more general point of view. It raises 
the question if physiological steroids may have an effect 
on the activity of sirtuins and further studies in that 
direction are awaited with great interest. 
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